Brought to you by 
Athersys finds new Japanese MultiStem partner in Healios
22 Jan 2016
Executive Summary
Athersys Inc. announced public Japanese regenerative medicine company Healios KK as its new MultiStem cell therapy partner in Japan. This comes shortly after Athersys ended its March 2015 MultiStem alliance with Chugai Pharmaceutical, which returned all rights to Athersys in October 2015 after the candidate failed to achieve the primary or component secondary endpoints in Phase II for stroke.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Manufacturing or Supply
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Athersys finds new Japanese MultiStem partner in Healios
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice